| Overview |
| bs-7885R-Cy3 |
| CCNDBP1 Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CCNDBP1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 23582 |
| Cytoplasm, Nucleus |
| Maternal inhibition of dferentiation; SECC 8; SSEC 8; CCDB1_HUMAN; CCNDBP 1; Ccndbp1; Cyclin D type binding protein 1; Cyclin-D1-binding protein 1; D type cyclin interacting protein 1; DIP 1; DIP1; GCIP; Grap 2 and cyclin D interacting protein; Grap 2 cyclin D interacting protein GCIP; Grap 2 cyclin interacting protein; Grap2 and cyclin D interacting protein; Grap2 and cyclin-D-interacting protein; Grap2 cyclin D interacting protein GCIP; Grap2 cyclin interacting protein; HHM protein; Human homolog of Maid; MAID; MAID protein; Stage specic embryonic cDNA 8. |
| May negatively regulate cell cycle progression. May act at least in part via inhibition of the cyclin-D1/CDK4 complex, thereby preventing phosphorylation of RB1 and blocking E2F-dependent transcription.Tissue specificity: Ubiquitously expressed. Expression is down-regulated in a variety of tumor types including breast, colon, prostate and rectal tumors, and is up-regulated in certain hepatic carcinomas. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz